Ellington Management Group’s Travere Therapeutics TVTX Stock Holding History

Ellington Management Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-12,900	Closed	-$188K	–	410
2020 Q1	$188K	Buy	+12,900	New	+$194K	0.04%	445
2017 Q2	–	Sell	-12,200	Closed	-$225K	–	912
2017 Q1	$225K	Buy	+12,200	New	+$239K	0.01%	543
2016 Q4	–	Sell	-15,500	Closed	-$347K	–	813
2016 Q3	$347K	Buy	+15,500	New	+$295K	0.1%	399

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ellington Management Group's TVTX Position: Q2 2020 in Review

Ellington Management Group sold out of Travere Therapeutics (TVTX) in Q2 2020, closing a stake of 12,900 shares — an estimated $188K sold.

Ellington Management Group first reported a position in TVTX in Q3 2016 and held it in 3 quarters. The position peaked at $347K in Q3 2016. 147 funds tracked by Wall St. Rank hold TVTX as of Q2 2020.

Ellington Management Group reported no remaining Travere Therapeutics position as of Q2 2020 after selling out during the quarter.
Ellington Management Group sold 12,900 Travere Therapeutics shares in Q2 2020, an estimated $188K.
Ellington Management Group first reported a position in Travere Therapeutics in Q3 2016 and held it in 3 quarters.
Ellington Management Group's Travere Therapeutics position peaked at $347K in Q3 2016.
147 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2020.

Based on Ellington Management Group's 13F filing for Q2 2020, filed 17 Aug 2020.